- Home
- NOTV vs ACHL Comparison
NOTV vs ACHL Comparison
Compare NOTV & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- ACHL
- Stock Information
- Founded
- NOTV 1974
- ACHL 2016
- Country
- NOTV United States
- ACHL United Kingdom
- Employees
- NOTV N/A
- ACHL N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NOTV Health Care
- ACHL Health Care
- Exchange
- NOTV Nasdaq
- ACHL Nasdaq
- Market Cap
- NOTV 46.2M
- ACHL 29.0M
- IPO Year
- NOTV 1997
- ACHL 2021
- Fundamental
- Price
- NOTV $1.34
- ACHL $0.71
- Analyst Decision
- NOTV Buy
- ACHL Hold
- Analyst Count
- NOTV 3
- ACHL 3
- Target Price
- NOTV $5.25
- ACHL $2.83
- AVG Volume (30 Days)
- NOTV 172.6K
- ACHL 49.8K
- Earning Date
- NOTV 08-08-2024
- ACHL 08-14-2024
- Dividend Yield
- NOTV N/A
- ACHL N/A
- EPS Growth
- NOTV N/A
- ACHL N/A
- EPS
- NOTV N/A
- ACHL N/A
- Revenue
- NOTV $501,062,000.00
- ACHL N/A
- Revenue This Year
- NOTV N/A
- ACHL N/A
- Revenue Next Year
- NOTV $8.69
- ACHL N/A
- P/E Ratio
- NOTV N/A
- ACHL N/A
- Revenue Growth
- NOTV N/A
- ACHL N/A
- 52 Week Low
- NOTV $1.29
- ACHL $0.63
- 52 Week High
- NOTV $11.42
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- NOTV 33.17
- ACHL 35.91
- Support Level
- NOTV $1.37
- ACHL $0.70
- Resistance Level
- NOTV $1.63
- ACHL $0.72
- Average True Range (ATR)
- NOTV 0.12
- ACHL 0.04
- MACD
- NOTV -0.00
- ACHL -0.00
- Stochastic Oscillator
- NOTV 14.71
- ACHL 54.05
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.